BNP Paribas reiterated their outperform rating on shares of Shire PLC (LON:SHP) in a research note published on Wednesday morning. BNP Paribas currently has a GBX 5,900 ($72.87) price objective on the biopharmaceutical company’s stock.
A number of other research firms have also recently weighed in on SHP. Societe Generale lowered their target price on shares of Shire PLC from GBX 6,500 ($80.28) to GBX 6,200 ($76.57) and set a buy rating on the stock in a research note on Monday, March 6th. Barclays PLC began coverage on shares of Shire PLC in a research note on Wednesday, March 8th. They issued an overweight rating and a GBX 6,500 ($80.28) target price on the stock. Royal Bank of Canada reissued an outperform rating on shares of Shire PLC in a research note on Monday, March 13th. Liberum Capital reissued a buy rating and issued a GBX 5,500 ($67.93) target price on shares of Shire PLC in a research note on Thursday, March 9th. Finally, Deutsche Bank AG reissued a buy rating on shares of Shire PLC in a research note on Tuesday, February 28th. One equities research analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Shire PLC currently has a consensus rating of Buy and a consensus target price of GBX 6,115.60 ($75.53).
Shire PLC (LON:SHP) opened at 4696.00 on Wednesday. Shire PLC has a 1-year low of GBX 2,707.19 and a 1-year high of GBX 5,377.00. The firm’s market cap is GBX 42.39 billion. The company’s 50 day moving average is GBX 4,761.49 and its 200-day moving average is GBX 4,764.24.
The business also recently announced a dividend, which will be paid on Tuesday, April 25th. Stockholders of record on Thursday, March 9th will be given a dividend of GBX 20.64 ($0.25) per share. This represents a dividend yield of 0.43%. This is a positive change from Shire PLC’s previous dividend of $3.51. The ex-dividend date is Thursday, March 9th.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.